Authors/Disclosures
|
Rita Kaspar
|
No disclosure on file |
|
Philippine Dana Peralta, MD
(US Air Force)
|
No disclosure on file |
|
Hugh D. Allen
(Nationwide Childrens)
|
No disclosure on file |
|
|
No disclosure on file |
|
John T. Kissel, MD, FAAN
|
Dr. Kissel has nothing to disclose. |
|
Kevin M. Flanigan, MD, FAAN
(Nationwide CHildrens Hospital)
|
Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care. |
|
Jing Wang, MD
(Children's Hospital Of Philadelphia)
|
No disclosure on file |
|
Jerry R. Mendell, MD, FAAN
(The Research Institute at Nationwide Children's Hospital)
|
Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta. |
|
|
No disclosure on file |